Intensive Therapy of Small Cell Lung Cancer: A Review of Recently Published Data

1999 ◽  
pp. 191-198
Author(s):  
J. Klastersky ◽  
D. Devriendt
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Intensive Therapy ◽  
Small Cell ◽  
Published Data ◽  
Small Cell Lung

Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer

Cancer ◽  
1982 ◽  
Vol 49 (2) ◽  
pp. 221-223 ◽  
Author(s):  
Edward C. Bradley ◽  
Geraldine P. Schechter ◽  
Mary J. Matthews ◽  
Jacqueline Whang-Peng ◽  
Martin H. Cohen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Intensive Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

scholarly journals Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data

2001 ◽  
Vol 85 (1) ◽  
pp. 14-22 ◽  
Author(s):  
D Choma ◽  
J-P Daurès ◽  
X Quantin ◽  
J L Pujol
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Published Data ◽  
Small Cell Lung

Tolerability and toxicity of adjuvant cisplatin and gemcitabine for non-small cell lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17504-e17504
Author(s):  
Xiao Li ◽  
Fan Yang ◽  
Guanchao Jiang ◽  
Jun Wang
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Published Data ◽  
Hematologic Toxicity ◽  
Adjuvant Setting ◽  
Small Cell Lung ◽  
Grade 3

e17504 Background: The combination of cisplatin and vinorelbine is the evidence supported regimen for adjuvant chemotherapy of non-small cell lung cancer (NSCLC). But this doublet has considerable toxicity and unfavorable tolerability, and resulted in poor compliance. Cisplatin and gemcitabine regimen is one of the most active and well tolerated regimens against advanced NSCLC, but its toxicity and tolerability have not been adequately evaluated in the adjuvant setting. Methods: From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m2) and gemcitabine (1250 mg/m2) between January 2005 and December 2011. Postoperative demographics, compliance to adjuvant therapy and toxicity were retrieved from medical records. Results: A total of 132 patients met the criteria and included in the study, 96 were males (72.7%)and 36 females (27.3%). Median age was 60.5 years (range, 29-75 years), and 41.7% patients were ≥65 years old. Overall, 68.2% received all four planned cycles, and cumulative dose delivered for gemcitabine was 8333 mg (83.3% planned) and cisplatin 248 mg (82.7% planned). There were no treatment-related deaths. Grade 3/4 neutropenia developed in 47 (35.6%) patients and was the predominant hematologic toxicity. Common grade 3/4 non-hematologic toxicities were nausea/vomiting (22.0%), infection (12.3%), and febrile neutropenia (11.4%). Conclusions: Cisplatin and gemcitabine are feasible in the adjuvant setting with favorable toxicity profile and superior tolerability compared with published data of cisplatin and vinorelbine.

scholarly journals Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

2021 ◽  
Vol 11 ◽  
Author(s):  
Karan Seegobin ◽  
Umair Majeed ◽  
Nathaniel Wiest ◽  
Rami Manochakian ◽  
Yanyan Lou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Objective Response ◽  
Standard Of Care ◽  
Small Cell ◽  
Published Data ◽  
Small Cell Lung ◽  
Current Standard ◽  
Lung Cancers

While first line targeted therapies are the current standard of care treatment for non-small cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire resistance to these agents over time. Immune check-point inhibitors (ICIs) have improved the outcomes of metastatic NSCLC, however, its efficacy in those with targetable drivers is largely unknown. In this manuscript, we reviewed the published data on ICI therapies in NSCLC with ALK, ROS1, BRAF, c-MET, RET, NTRK, KRAS, and HER2 (ERBB2) alterations. We found that the objective response rates (ORRs) associated with ICI treatments in lung cancers harboring the BRAF (0–54%), c-MET (12–49%), and KRAS (18.7-66.7%) alterations were comparable to non-mutant NSCLC, whereas the ORRs in RET fusion NSCLC (less than10% in all studies but one) and ALK fusion NSCLC (0%) were relatively low. The ORRs reported in small numbers of patients and studies of ROS1 fusion, NTRK fusion, and HER 2 mutant NSCLC were 0–17%, 50% and 7–23%, respectively, making the efficacy of ICIs in these groups of patients less clear. In most studies, no significant correlation between treatment outcome and PD-L1 expression or tumor mutation burden (TMB) was identified, and how to select patients with NSCLC harboring actionable mutations who will likely benefit from ICI treatment remains unknown.

Sign in / Sign up

Export Citation Format

Share Document